VANCOUVER, British Columbia, April 27, 2015 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (" Aquinox ") (Nasdaq: AQXP ), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that David Main, Aquinox's President & CEO, will present a corporate overview at the upcoming 2015 Bloom Burton & Co. Healthcare Investor Conference on Tuesday , May 5 th at 11:00 AM Eastern Time . The conference will take place at the Sheraton Centre in Toronto, ON.
The corporate overview being presented will be available at www.aqxpharma.com .
About Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Aquinox's lead drug candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. Having successfully completed multiple preclinical studies and clinical trials with AQX-1225, Aquinox is now advancing through Phase 2 development. Aquinox has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1. For more information, please visit www.aqxpharma.com .
Investor Contact Info:
Brendan Payne Senior Manager, Investor Relations Aquinox Pharmaceuticals, Inc. 604.629.9223 Ext. 109 ir@aqxpharma.com
Communications C ontact Info:
Bianca Nery Senior Account Executive MacDougall Biomedical Communications 650.339.7533 aquino x@macbiocom.com